Masonic Medical Research Laboratory, Utica, NY.
Circ Arrhythm Electrophysiol. 2010 Feb;3(1):88-95. doi: 10.1161/CIRCEP.109.886275. Epub 2009 Dec 1.
Amiodarone and ranolazine have been characterized as inactivated- and activated-state blockers of cardiac sodium channel current (I(Na)), respectively, and shown to cause atrial-selective depression of I(Na)-related parameters. This study tests the hypothesis that their combined actions synergistically depress I(Na)-dependent parameters in atria but not ventricles.
The effects of acute ranolazine (5 to 10 micromol/L) were studied in coronary-perfused right atrial and left ventricular wedge preparations and superfused left atrial pulmonary vein sleeves isolated from chronic amiodarone-treated (40 mg/kg daily for 6 weeks) and untreated dogs. Floating and standard microelectrode techniques were used to record transmembrane action potentials. When studied separately, acute ranolazine and chronic amiodarone caused atrial-predominant depression of I(Na)-dependent parameters. Ranolazine produced a much greater reduction in V(max) and much greater increase in diastolic threshold of excitation and effective refractory period in atrial preparations isolated from amiodarone-treated versus untreated dogs, leading to a marked increase in postrepolarization refractoriness. The drug combination effectively suppressed triggered activity in pulmonary vein sleeves but produced relatively small changes in I(Na)-dependent parameters in the ventricle. Acetylcholine (0.5 micromol/L) and burst pacing induced atrial fibrillation in 100% of control atria, 75% of ranolazine-treated (5 micromol/L) atria, 16% of atria from amiodarone-treated dogs, and in 0% of atria from amiodarone-treated dogs exposed to 5 micromol/L ranolazine.
The combination of chronic amiodarone and acute ranolazine produces a synergistic use-dependent depression of I(Na)-dependent parameters in isolated canine atria, leading to a potent effect of the drug combination to prevent the induction of atrial fibrillation.
胺碘酮和雷诺嗪分别被描述为心脏钠离子通道电流(I(Na))的失活和激活状态阻滞剂,并显示出导致心房选择性抑制与 I(Na)相关参数。本研究检验了它们的联合作用是否能协同抑制心房而非心室中的 I(Na)依赖性参数的假设。
在冠状动脉灌注的右心房和左心室楔形切片以及从慢性胺碘酮处理(40mg/kg 每日 6 周)和未处理的狗中分离的左心房肺静脉袖套中研究了急性雷诺嗪(5 至 10 微摩尔/升)的作用。使用漂浮和标准微电极技术记录跨膜动作电位。当分别研究时,急性雷诺嗪和慢性胺碘酮导致心房为主的 I(Na)依赖性参数的抑制。雷诺嗪在从胺碘酮处理的狗中分离的心房制剂中引起 Vmax 的更大降低和舒张期兴奋阈和有效不应期的更大增加,导致后除极期不应期的显著增加。药物组合有效地抑制了肺静脉袖套中的触发活动,但在心室中对 I(Na)依赖性参数的变化相对较小。乙酰胆碱(0.5 微摩尔/升)和爆发起搏导致 100%的对照心房、75%的雷诺嗪处理(5 微摩尔/升)心房、16%的胺碘酮处理狗的心房和 0%的胺碘酮处理狗的心房发生心房颤动。
慢性胺碘酮和急性雷诺嗪的联合使用导致犬心房中 I(Na)依赖性参数的协同、使用依赖性抑制,导致药物联合的强大作用以防止心房颤动的诱导。